Polyhydroxylated Benzophenones for HDAC1 Activation in Neurodegeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders lack effective methods to activate histone deacetylase 1 (HDAC1) enzymatic activity, which is crucial for preventing neurodegeneration and maintaining DNA integrity in neurons.
Innovation Solution
Development of polyhydroxylated benzophenone compounds, specifically exifone, which increases HDAC1 deacetylase activity and is used in pharmaceutical compositions to treat neurological disorders by activating HDAC1, thereby addressing deficiencies in HDAC1 deacetylase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurodegenerative disorders, then existing therapeutic options are maintained, but HDAC1 enzymatic activity cannot be activated
Solution Approach 1:
The patent applies parameter changes by developing polyhydroxylated benzophenone compounds with specific molecular structures (Formula I and Formula II) that have optimized parameters for HDAC1 activation. The compounds feature specific hydroxyl group positions and substitutions that enhance their ability to activate HDAC1 enzymatic activity, thereby resolving the contradiction between maintaining treatment versatility and achieving reliable HDAC1 activation.
2Reliability
If HDAC1 activity is not activated, then current treatment protocols are maintained, but neurodegeneration prevention is insufficient
Solution Approach 1:
The patent introduces polyhydroxylated benzophenone compounds as intermediary substances that mediate between existing treatment protocols and HDAC1 activation. These compounds serve as the missing link that enables HDAC1 activation without requiring complex changes to existing treatment frameworks, thus improving neurodegeneration prevention while avoiding excessive treatment mechanism complexity.
3Reliability
If polyhydroxylated benzophenone compounds are developed, then HDAC1 activation is achieved, but compound structure complexity increases
Solution Approach 1:
The patent applies local quality by introducing hydroxyl groups at specific positions on the benzophenone core structure (Formula I and Formula II). Rather than uniformly complexing the entire molecule, the hydroxyl substitutions are strategically placed to maximize HDAC1 activation while maintaining reasonable structural simplicity. This localized modification approach achieves reliable HDAC1 activation without excessive overall compound complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Exifone effectively activates HDAC1, leading to enhanced deacetylation rates and neuroprotective effects, including protection from DNA damage, amelioration of neuronal loss, and improvement of cognitive functions in animal models of neurodegenerative diseases.
Implementation Method 1
exifone, increases the deacetylase activity of HDAC1... exifone increases the rate of deacetylation reaction by HDAC1
Data Source
AI summary
The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.